Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Hematology"
DOI: 10.1007/s12185-020-02843-8
Abstract: We herein report the results of the New TARGET study 2nd-line, which collected data on patients with chronic-phase (CP) chronic myeloid leukemia (CML) who received a 2nd-line tyrosine kinase inhibitor (TKI) because of resistance and/or… read more here.
Keywords: 2nd line; line; kinase; line tki ... See more keywords
Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz255.041
Abstract: Abstract Background In phase III trials, the results of ipilimumab plus nivolumab combination therapy (IPI+NIVO) are promising for metastatic melanoma (MM), despite many treatment-related grade 3-4 adverse events (AEs). Here, we report real-world outcomes of… read more here.
Keywords: ipi nivo; bms advisory; advisory consultancy; 1st line ... See more keywords
FRI0467 DRUG SURVIVAL AND SAFETY OF BIOLOGICAL THERAPIES IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.4655
Abstract: Biological treatment (BT) has changed perspectives of JIA patients. Increasing data from real life experience have been reported.To compare drug survival, safety and efficacy of BT in patients with Juvenile Idiopathic Arthritis (JIA).A retrospective observational… read more here.
Keywords: decade; 1st decade; arthritis; line ... See more keywords
Chemotherapy efficacy in metastatic colorectal cancer (mCRC) patients treated with adjuvant or first-line FOLFOX-based chemotherapy.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e15048
Abstract: e15048Background: Efficacy results of Folfox or Folfiri chemotherapies (CT) are not different as 1st line in mCRC patients, alone or with targeted therapies. No data reported on progression-free survival (PFS) of 1st line Folfiri after… read more here.
Keywords: chemotherapy; line; efficacy; folfox based ... See more keywords
Targeting bacteroides in the stool microbiome and response to treatment (Rx) with first-line VEGFTKI in metastatic renal cell carcinoma (mRCC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.584
Abstract: 584Background: Diarrhea occurs in ~50% patients with mRCC receiving VEGFTKIs, and is a common cause of VEGFTKI Rx dose reductions/delays/interruptions. Stool bacteroides level directly correlates with diarrhea in these patients on Rx with VEGFTKI (Pal… read more here.
Keywords: mrcc; vegftki; line vegftki; targeting bacteroides ... See more keywords
Time from diagnosis to 1st line immunotherapy (IOT) and its challenges, in a retrospective, multicenter study of Israeli patients (pts) with advanced non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e19346
Abstract: e19346Background: The importance of timely treatment of advanced NSCLC and timeline measurements have been the subject of reported studies. Real world evidence data (RWED) via EHR and cutting-edge ... read more here.
Keywords: line immunotherapy; time diagnosis; iot challenges; diagnosis 1st ... See more keywords
The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression-free survival in patients with advanced EGFR-mutated NSCLC.
Sign Up to like & getrecommendations! Published in 2020 at "Oncology letters"
DOI: 10.3892/ol.2020.11535
Abstract: The present study aimed to evaluate the total progression-free survival (PFS) time of the 1st-line chemotherapy (CHT)/2nd-line tyrosine kinase inhibitor (TKI) and 1st-line TKI/2nd-line CHT therapeutic regimens. Data from patients with non-small-cell lung cancer (NSCLC)… read more here.
Keywords: 2nd line; line; line cht; line tki ... See more keywords